Redhill Biopharma (Redhill Biopharma) COGS-to-Revenue : 0.45 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma COGS-to-Revenue?

Redhill Biopharma's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.81 Mil. Its Revenue for the three months ended in Jun. 2023 was $1.80 Mil.

Redhill Biopharma's COGS to Revenue for the three months ended in Jun. 2023 was 0.45.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Redhill Biopharma's Gross Margin % for the three months ended in Jun. 2023 was 55.12%.

Redhill Biopharma COGS-to-Revenue Historical Data

The historical data trend for Redhill Biopharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma COGS-to-Revenue Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.36

0.57

0.58

0.54

0.53

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.54	0.67	0.45	0.45	-

Redhill Biopharma COGS-to-Revenue Calculation

Redhill Biopharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.459	/	6.53
	=	0.53

Redhill Biopharma's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.806	/	1.796
	=	0.45

Redhill Biopharma (NAS:RDHL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Redhill Biopharma's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.806 / 1.796
	=	55.12 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Redhill Biopharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.